Phase I study of (6R)-5,10-dideazatetrahydrofolate: a folate antimetabolite inhibitory to de novo purine synthesis.
about
Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibitPhase I dose-escalation and pharmacokinetic study of a novel folate analogue AG2034One-carbon metabolism and nucleotide biosynthesis as attractive targets for anticancer therapy.Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors and the proton-coupled folate transporter over theNew agents in cancer clinical trials.The human proton-coupled folate transporter: Biology and therapeutic applications to cancer.Role of membrane folate-binding protein in the cytotoxicity of 5,10-dideazatetrahydrofolic acid in human ovarian carcinoma cell lines in vitroFolate during antifolate chemotherapy: what we know... and do not know.6-Substituted Pyrrolo[2,3-d]pyrimidine Thienoyl Regioisomers as Targeted Antifolates for Folate Receptor α and the Proton-Coupled Folate Transporter in Human TumorsNovel 5-substituted pyrrolo[2,3-d]pyrimidines as dual inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase and as potential antitumor agents.Targeting Nonsquamous Nonsmall Cell Lung Cancer via the Proton-Coupled Folate Transporter with 6-Substituted Pyrrolo[2,3-d]Pyrimidine Thienoyl Antifolates.Tumor Targeting with Novel 6-Substituted Pyrrolo [2,3-d] Pyrimidine Antifolates with Heteroatom Bridge Substitutions via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide BiosySynthesis and biological activity of a novel series of 6-substituted thieno[2,3-d]pyrimidine antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors over the reduced folate carrier and proton-coupled folate tSynthesis and discovery of high affinity folate receptor-specific glycinamide ribonucleotide formyltransferase inhibitors with antitumor activity.Tumor-targeting with novel non-benzoyl 6-substituted straight chain pyrrolo[2,3-d]pyrimidine antifolates via cellular uptake by folate receptor α and inhibition of de novo purine nucleotide biosynthesis.Structural and Enzymatic Analysis of Tumor-Targeted Antifolates That Inhibit Glycinamide Ribonucleotide Formyltransferase.The major facilitative folate transporters solute carrier 19A1 and solute carrier 46A1: biology and role in antifolate chemotherapy of cancer.Humanizing mouse folate metabolism: conversion of the dual-promoter mouse folylpolyglutamate synthetase gene to the human single-promoter structure.A defect in the p53 response pathway induced by de novo purine synthesis inhibition.New antimetabolites in cancer chemotherapy and their clinical impactSelective potentiation of lometrexol growth inhibition by dipyridamole through cell-specific inhibition of hypoxanthine salvage.Cancer chemotherapy: targeting folic acid synthesis.Cellular folates prevent polyglutamation of 5, 10-dideazatetrahydrofolate. A novel mechanism of resistance to folate antimetabolites.The promise and challenges of exploiting the proton-coupled folate transporter for selective therapeutic targeting of cancer.
P2860
Q24631090-C72F1914-023F-4136-9969-AFC1B33566A1Q28346782-A4234AFE-D8A2-4057-8980-141CE39DDC24Q33618935-924FC845-143B-42BB-9116-23E78BFB0BCCQ33720633-87DBD9C6-1CA7-47A8-981F-59B6E997D34FQ34293629-27D830D3-4071-499C-ACE3-E4A73E6CD787Q34297931-7C8B1340-FA0E-4473-8A6B-AEA8B0E92F25Q36135049-2EB996B0-CC6A-418F-B1DA-6B1B35974FC8Q36278412-D483452C-1651-41A2-93CC-3D222253DF47Q36467564-008A695C-9FB4-49EC-AF9F-01FEF730AA60Q36467569-CC3300A9-3133-4B4B-8780-0C5F1EEB44D2Q36733474-F9218614-B80C-4E3C-974D-6463E6597BCEQ37246257-FA655E6D-1C6F-4CEB-A0F6-EBD6CC8B9B78Q37313482-4F122D0F-AC74-476B-B06E-F4316DAD2B6BQ37356225-7F6B7828-1844-4362-B948-20F37CC4EDECQ37432606-605DAD80-D92E-4F87-8B18-EE52CF03E0F9Q37587969-828CEEC0-4464-4E37-9105-38AE2A242BCDQ37663377-37867C05-6FAD-4A0E-B255-443FA7D36E74Q37702952-8517BA5F-B76F-40CE-920F-DF8303FFD884Q38349842-E0BC9AC6-ACAC-4B5B-B9FC-1BA44E97C494Q39702086-E59A96F5-130E-4CC2-8964-E0D4294EE7FDQ41931729-C7DE27F5-42E2-4E1C-A09D-EA93965F803AQ42588769-6DB9C552-05F1-44BD-8ADA-BBAAD57714FAQ46728526-CC329B90-68CB-4D0E-ADBF-6DFCEB86775FQ50062142-D4193290-F1EC-4536-A6CA-F0960F225A43
P2860
Phase I study of (6R)-5,10-dideazatetrahydrofolate: a folate antimetabolite inhibitory to de novo purine synthesis.
description
1993 nî lūn-bûn
@nan
1993 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1993 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
name
Phase I study of (6R)-5,10-did ...... y to de novo purine synthesis.
@ast
Phase I study of (6R)-5,10-did ...... y to de novo purine synthesis.
@en
type
label
Phase I study of (6R)-5,10-did ...... y to de novo purine synthesis.
@ast
Phase I study of (6R)-5,10-did ...... y to de novo purine synthesis.
@en
prefLabel
Phase I study of (6R)-5,10-did ...... y to de novo purine synthesis.
@ast
Phase I study of (6R)-5,10-did ...... y to de novo purine synthesis.
@en
P2093
P356
P1476
Phase I study of (6R)-5,10-did ...... y to de novo purine synthesis.
@en
P2093
P304
P356
10.1093/JNCI/85.14.1154
P407
P577
1993-07-01T00:00:00Z